SecBot SecBot
6-K ·Filed Jul 15, 2026

DRTS

Alpha Tau Medical Ltd.
BULLISH
Impact 5/10
Horizonweeks Processed4mo ago SEC0001213900-26-078138
Notable filing: 6-K
Actionable Insight ▲ Bullish

This is an early clinical milestone with no efficacy data yet. The FDA registration pathway for Alpha DaRT in this indication remains unclear. Monitor for initial ORR data from ADMIRE and any updates from the ReSTART trial. The company has a $1.1B market cap with no revenue, so clinical progress is the primary driver.

DirectionBullish
Confidencemedium
Horizonweeks

Alpha DaRT

▲ Bullish Named in this 6-K
Impact
Phase
Pivotal (PMA submission ongoing for cSCC); Phase 2 pilot for glioblastoma (REGAIN); Pilot for pancreatic cancer (IMPACT)
Time to market
The ReSTART pivotal trial for recurrent cSCC completed enrollment in May 2026 and the first PMA module was submitted in January 2026. If the modular PMA process proceeds smoothly, a US approval decision could come in late 2027 or 2028. Alpha DaRT already has marketing approval in Japan for head and neck cancer and in Israel for SCC of the skin and oral cavity.
Next catalyst
None dated

What to watchThe REGAIN interim data (all 8 patients alive, median survival not reached at 6.9 months follow-up) was released Nov 15, with an investor call on Nov 16. The next major catalyst is the IMPACT pancreatic cancer pilot study data expected in early 2027, and continued progress on the modular PMA submission for cSCC. Q3 2026 earnings are scheduled for Nov 24. Watch for any PMA submission completion announcements for cSCC, which would mark the clearest path to a US approval decision.

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$12.46
T+0 close · Jul 15, 2026 · via day close
Latest settled
+12.36%
T+60 · $14.00
Vs SPY
+9.83%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 15 $12.46entry
  2. T+1 · 4mo ago −4.65%α −4.11% · $11.88
  3. T+5 · 4mo ago +4.41%α +5.39% · $13.01
  4. T+20 · 3mo ago +11.32%α +8.97% · $13.87
  5. T+60 · 6w ago +12.36%α +9.83% · $14.00
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Alpha Tau announced the successful treatment of the first patient in its ADMIRE study, evaluating Alpha DaRT for immunocompromised patients with recurrent cutaneous squamous cell carcinoma (cSCC). The study targets a high-need population with limited treatment options and builds on momentum from the recently completed ReSTART pivotal trial. This is an early clinical milestone with no efficacy data reported.

Key Facts

  • First patient treated in ADMIRE study at Banner MD Anderson Cancer Center
  • ADMIRE is a prospective, single-arm study enrolling up to 28 immunocompromised patients with recurrent cSCC
  • Primary endpoint: objective response rate (ORR) per RECIST v1.1; secondary endpoints include PFS, OS, and local control over 12 months
  • ReSTART pivotal trial for recurrent cSCC recently completed patient enrollment
  • Immunocompromised patients face 65- to 100-fold higher incidence of cSCC (organ transplant recipients)

Financial Impact

Clinical milestone; no revenue or financial data provided in the filing.

Risk Factors

  • Clinical trial failure risk, no efficacy data from ADMIRE reported yet
  • Small sample size (up to 28 patients) limits statistical power
  • Regulatory approval for Alpha DaRT in this indication is uncertain and likely years away
  • Company is pre-revenue with significant operating losses (per 20-F risk factors)

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
82% bullish (11 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001213900-26-078138
Document: ea0297988-6k_alpha.htm0001213900-26-078138
Document: 0001213900-26-078138-index-headers.html0001213900-26-078138
Document: 0001213900-26-078138-index.html0001213900-26-078138
Document: 0001213900-26-078138.txt0001213900-26-078138

US Market Status

Market Closed · Opens in 7h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 15, 2026